During the last meeting of the European School of Hematology, I had a lovely chat with Professor Philippe Moreau about the latest developments in the field of multiple myeloma, and we went through the latest EHA-ESMO guidelines.
And this is really amazing because in the transplant-eligible patient, we discussed the advent and efficacy of novel induction regimens, the quadruplet regimens with anti-CD38 and the triplet VTD or VRd, dara-VTD, daratumumab-VRd...
During the last meeting of the European School of Hematology, I had a lovely chat with Professor Philippe Moreau about the latest developments in the field of multiple myeloma, and we went through the latest EHA-ESMO guidelines.
And this is really amazing because in the transplant-eligible patient, we discussed the advent and efficacy of novel induction regimens, the quadruplet regimens with anti-CD38 and the triplet VTD or VRd, dara-VTD, daratumumab-VRd. We also discussed the advances in the non-transplant-eligible population and, obviously, the use of anti-CD38-based combinations is also now becoming more and more standard of care, dara-rev-dex, daratumumab-lenalidomide-dexamethasone, or daratumumab-bortezomib-melphalan-prednisone, dara-VMP. We also, of course, discussed the different treatment options at the time of relapse with a special focus on the lenalidomide-refractory patient, where we do have now some good and effective combinations like daratumumab-carfilzomib-dex. This is a CANDOR trial. Isatuximab-carfilzomib-dex, the IKEMA trial, or daratumumab-pomalidomide-dexamethasone, APOLLO trial, or isatuximab-pomalidomide-dex. This is the ICARIA trial.
Last but not least, of course, we could not skip the role of immune therapy, whether CAR T-cells. One construct has just been approved, but also the advent of bispecific antibodies, but also antibody-drug conjugates. So really it’s a fascinating new era for multiple myeloma, and this is really great news for the patient and for all of us in the myeloma space.